These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 33484864

  • 1. Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia.
    Torres A, Garrity-Ryan L, Kirsch C, Steenbergen JN, Eckburg PB, Das AF, Curran M, Manley A, Tzanis E, McGovern PC.
    Int J Infect Dis; 2021 Mar; 104():501-509. PubMed ID: 33484864
    [Abstract] [Full Text] [Related]

  • 2. Omadacycline for Community-Acquired Bacterial Pneumonia.
    Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E.
    N Engl J Med; 2019 Feb 07; 380(6):517-527. PubMed ID: 30726692
    [Abstract] [Full Text] [Related]

  • 3. Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice.
    Ramirez JA, Tzanis E, Curran M, Noble R, Chitra S, Manley A, Kirsch C, McGovern PC.
    Clin Infect Dis; 2019 Aug 01; 69(Suppl 1):S33-S39. PubMed ID: 31367741
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
    File TM, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, Seltzer E, Paukner S, Wicha WW, Talbot GH, Gasink LB.
    Clin Infect Dis; 2019 Nov 13; 69(11):1856-1867. PubMed ID: 30722059
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial.
    Pai MP, Wilcox M, Chitra S, McGovern P.
    Respir Med; 2021 Aug 13; 184():106442. PubMed ID: 34058682
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment.
    Cornely OA, File TM, Garrity-Ryan L, Chitra S, Noble R, McGovern PC.
    Int J Antimicrob Agents; 2021 Feb 13; 57(2):106263. PubMed ID: 33326848
    [Abstract] [Full Text] [Related]

  • 7. Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection.
    Lodise TP, Mistry R, Young K, LaPensee K.
    Clin Drug Investig; 2021 Mar 13; 41(3):269-275. PubMed ID: 33604769
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study.
    Ramirez J, Deck DH, Eckburg PB, Curran M, Das AF, Kirsch C, Manley A, Tzanis E, McGovern PC.
    Open Forum Infect Dis; 2021 Jun 13; 8(6):ofab135. PubMed ID: 34160474
    [Abstract] [Full Text] [Related]

  • 9. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
    Paukner S, Goldberg L, Alexander E, Das AF, Heinrich S, Patel P, Moran GJ, Sandrock C, File TM, Vidal JE, Waites KB, Gelone SP, Schranz J.
    J Glob Antimicrob Resist; 2022 Jun 13; 29():434-443. PubMed ID: 34788694
    [Abstract] [Full Text] [Related]

  • 10. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM, Rewerska B, Vucinic-Mihailovic V, Gonong JRV, Das AF, Keedy K, Taylor D, Sheets A, Fernandes P, Oldach D, Jamieson BD.
    Clin Infect Dis; 2016 Oct 15; 63(8):1007-1016. PubMed ID: 27448679
    [Abstract] [Full Text] [Related]

  • 11. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
    File TM, Alexander E, Goldberg L, Das AF, Sandrock C, Paukner S, Moran GJ.
    BMC Pulm Med; 2021 May 08; 21(1):154. PubMed ID: 33964925
    [Abstract] [Full Text] [Related]

  • 12. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
    Zhanel GG, Esquivel J, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, Hink R, Berry L, Schweizer F, Zhanel MA, Bay D, Lagacé-Wiens PRS, Walkty AJ, Lynch JP, Karlowsky JA.
    Drugs; 2020 Feb 08; 80(3):285-313. PubMed ID: 31970713
    [Abstract] [Full Text] [Related]

  • 13. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
    O'Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, Eckburg PB, Manley A, Steenbergen JN, Tzanis E, McGovern PC, Loh E, OASIS-2 Investigators.
    Lancet Infect Dis; 2019 Oct 08; 19(10):1080-1090. PubMed ID: 31474458
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
    Barrera CM, Mykietiuk A, Metev H, Nitu MF, Karimjee N, Doreski PA, Mitha I, Tanaseanu CM, Molina JM, Antonovsky Y, Van Rensburg DJ, Rowe BH, Flores-Figueroa J, Rewerska B, Clark K, Keedy K, Sheets A, Scott D, Horwith G, Das AF, Jamieson B, Fernandes P, Oldach D, SOLITAIRE-ORAL Pneumonia Team.
    Lancet Infect Dis; 2016 Apr 08; 16(4):421-30. PubMed ID: 26852726
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S, Nenninger A, Sheets A, Keedy K, Lawrence L, Quintas M, Cammarata S.
    Int J Infect Dis; 2020 Aug 08; 97():374-379. PubMed ID: 32534142
    [Abstract] [Full Text] [Related]

  • 18. Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial.
    LoVecchio F, Schranz J, Alexander E, Mariano D, Meads A, Sandrock C, Moran GJ, Giordano PA.
    J Emerg Med; 2021 Jun 08; 60(6):781-792. PubMed ID: 33731270
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.